Adjunctive Risperidone Treatment Did Not Reduce PTSD Symptoms

Currently, the only FDA approved pharmacotherapy for the treatment of PTSD are SRIs.  However, in clinical practice, antipsychotics are commonly prescribed for antidepressant-resistant symptoms of PTSD.  The purpose of this study was to determine the efficacy of risperidone as an adjunct to treatment for Veterans with chronic, military-related PTSD.  The 6-month randomized controlled trial found no difference between the treatment and controlled groups suggesting that treatment with risperdone did not reduce PTSD symptoms. 

Access the full article in the August issue of the Journal of the American Medical Association (JAMA. 2011 Aug 3;306(5):493-502).